Tanespimycin (17-AAG)

Name: Tanespimycin (17-AAG)
Brand: Selleck Chemicals
SKU: S1141
Rating: 5 (56 reviews)

For research use only. Not for use in humans.

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

56 publications

Tanespimycin (17-AAG) Chemical Structure

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Selleck's Tanespimycin (17-AAG) has been cited by 56 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Mol Cell, 2019, 75(4):823-834

PubMed: 31302001 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5043

PubMed: 31695040 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):737

PubMed: 31570706 ( click the link to review the publication )

Cells, 2019, 8(8)

PubMed: 31370342 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:2050183

PubMed: 31178953 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.29283

PubMed: 31595984 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(2):220-233

PubMed: 31516744 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5637

PubMed: 30948782 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(2):312-324

PubMed: 30745823 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 371:63-73

PubMed: 30953615 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):102

PubMed: 30678647 ( click the link to review the publication )

Exp Eye Res, 2019, 189:107821

PubMed: 31589841 ( click the link to review the publication )

J Natl Cancer Inst, 2018, 110(4):390-399

PubMed: 29202196 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 47(6):2199-2215

PubMed: 29975948 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):1051-1060

PubMed: 29440291 ( click the link to review the publication )

Mycoses, 2018, 61(11):853-856

PubMed: 29998564 ( click the link to review the publication )

F1000Res, 2018, 7:1906

PubMed: 30881689 ( click the link to review the publication )

EMBO J, 2017, 36(5):646-663

PubMed: 28093501 ( click the link to review the publication )

ACS Photonics, 2017, 5(2):487-494

PubMed: 29805987 ( click the link to review the publication )
Br J Pharmacol, 2017, 174(5):409-423

PubMed: 28052321 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(3):543-554

PubMed: 27592300 ( click the link to review the publication )

Sci Rep, 2017, 7(1):4546

PubMed: 28674407 ( click the link to review the publication )

Am J Transl Res, 2017, 9(11):4945-4953

PubMed: 29218092 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:2219-2226

PubMed: 28458565 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

Cell, 2017, 170(5):845-859

PubMed: 28823557 ( click the link to review the publication )

Nat Commun, 2016, 7:13122

PubMed: 27959342 ( click the link to review the publication )

Cancer Res, 2016, 76(4):965-73

PubMed: 26676744 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Biochem J, 2016, 473(12):1733-44

PubMed: 27059856 ( click the link to review the publication )

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(17):14796-813

PubMed: 26142707 ( click the link to review the publication )

Oncotarget, 2015, 51: S659-S660

PubMed: ( click the link to review the publication )

Mol Cancer, 2014, 15:30

PubMed: 24927996 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(10):2237-41

PubMed: 25140805 ( click the link to review the publication )

Exp Gerontol, 2014, 52:55-69

PubMed: 24486130 ( click the link to review the publication )

Insect Mol Biol, 2014, 23(6):720-32

PubMed: 25060629 ( click the link to review the publication )

Julius Maximilians Universit, 2014, Kumari G

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(12):4269-82

PubMed: 24962213 ( click the link to review the publication )

Mol Cell, 2013, 50(3):368-78

PubMed: 23583076 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1830(11):5184-92

PubMed: 23850472 ( click the link to review the publication )

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2013, 10.1165/rcmb.2013-0214OC

PubMed: 24303801 ( click the link to review the publication )
Sci Transl Med, 2012, 4(120):120ra17

PubMed: 22277784 ( click the link to review the publication )

J Exp Med, 2012, 209(2):259-73

PubMed: 22271575 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(4):911-9

PubMed: 22306003 ( click the link to review the publication )

J Biol Chem, 2012, 287(53):44109-20

PubMed: 23144451 ( click the link to review the publication )

Eukaryot Cell, 2012, 11(11):1324-32

PubMed: 22822234 ( click the link to review the publication )

Age (Dordr), 2012, 35(3):549-62

PubMed: 22252435 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(18):7535-40

PubMed: 21502504 ( click the link to review the publication )

J Nat Prod, 2011, 74(6):1491-9

PubMed: 21553813 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Features

Displays very low toxicity toward normal cells.

Targets

HSP90 ^[1]
(Cell-free assay)

5 nM

In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. ^[1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. ^[2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A549	Mlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{f1PGlEPTB;MD6wNFA{ODNizszN	NUfQXHBOW0GQR1XS
IST-MEL1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{i1e2lEPTB;MD6wNFA1ODdizszN	MXXTRW5ITVJ?
NCI-SNU-1	MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVG0c5VTUUN3ME2wMlAxOjB5IN88US=>	MlzXV2FPT0WU
FADU	M2jFPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rDSWlEPTB;MD6wNFIxQSEQvF2=	MlfOV2FPT0WU
C32	NHTCO5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\BcVBKSzVyPUCuNFA{ODRizszN	NVfFRoNSW0GQR1XS
D-566MG	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnVTWM2OD1yLkCwN\|kh\|ryP	MXLTRW5ITVJ?
LXF-289	NEHicW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXPTWM2OD1yLkCwOFE6KM7:TR?=	MYXTRW5ITVJ?
HGC-27	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;rRY9KSzVyPUCuNFA2OSEQvF2=	MWfTRW5ITVJ?
RPMI-7951	NUCzSFh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjlcWk4UUN3ME2wMlAxPzF5IN88US=>	NUTPVHhzW0GQR1XS
HSC-3	M4XNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzhTWM2OD1yLkCwPVI6KM7:TR?=	NUnCNnRUW0GQR1XS
MIA-PaCa-2	NYnFWXhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTBwMEGwNFkh\|ryP	NVzwOplnW0GQR1XS
KS-1	NGrvdplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwMEGzOVUh\|ryP	MX7TRW5ITVJ?
CAL-51	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPtVGJKSzVyPUCuNFE1ODVizszN	M3fRd3NCVkeHUh?=
MDA-MB-361	M131d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnr4TWM2OD1yLkCxOFk2KM7:TR?=	MUfTRW5ITVJ?
TI-73	MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwMEG3PVYh\|ryP	MoXWV2FPT0WU
AGS	NX61RZl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlH3TWM2OD1yLkCxPVM5KM7:TR?=	NH\jOZFUSU6JRWK=
NCI-H460	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTBwMEG5O\|Qh\|ryP	NYPlcFlKW0GQR1XS
A204	NXL2XFd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTBwMEKyOFkh\|ryP	NGnG[phUSU6JRWK=
CHL-1	M1nUcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwMEKyOVEh\|ryP	M320PHNCVkeHUh?=
DU-4475	MlHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XZXWlEPTB;MD6wNlI3OSEQvF2=	MoXDV2FPT0WU
CGTH-W-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHZTWM2OD1yLkCyN\|Q6KM7:TR?=	MlnxV2FPT0WU
HCC2218	M32zTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTncYZGUUN3ME2wMlAzPDl2IN88US=>	MnyxV2FPT0WU
A2780	Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;wNIlyUUN3ME2wMlAzPTNzIN88US=>	NVuzOo9XW0GQR1XS
NCI-H720	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnRR3ZKSzVyPUCuNFI2PDZizszN	M3vJOHNCVkeHUh?=
NCI-N87	M4ToVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXSx[GFiUUN3ME2wMlAzPTl\|IN88US=>	NWS1c5J5W0GQR1XS
CHP-212	NXn2ZYhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzIXI1KSzVyPUCuNFI3OjhizszN	NH3nVZhUSU6JRWK=
NCI-H23	NWLZUZRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHCTWM2OD1yLkCyOlY2KM7:TR?=	NITQe5VUSU6JRWK=
D-263MG	NF:y[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3XNZUyUUN3ME2wMlAzPzh4IN88US=>	NVu0cIU5W0GQR1XS
ME-180	M1HBOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVX0WpJLUUN3ME2wMlAzQDlzIN88US=>	M1XheHNCVkeHUh?=
SW982	MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13uV2lEPTB;MD6wNlk6QSEQvF2=	M3i3THNCVkeHUh?=
OE19	NVfk[5Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjOZpE3UUN3ME2wMlA{ODd5IN88US=>	MonqV2FPT0WU
SK-LU-1	Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTudWhXUUN3ME2wMlA{ODh{IN88US=>	NHnUW3lUSU6JRWK=
H4	M{\ZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnoTWM2OD1yLkCzNFkh\|ryP	M1np[3NCVkeHUh?=
HT-144	NHfyeoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTBwMEOwPVMh\|ryP	NYeydlg2W0GQR1XS
SK-UT-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vFTmlEPTB;MD6wN\|E4QCEQvF2=	MmXjV2FPT0WU
D-336MG	MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\OfGlEPTB;MD6wN\|MxQSEQvF2=	M16ySnNCVkeHUh?=
MDA-MB-175-VII	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\6VGlEPTB;MD6wN\|M2PCEQvF2=	NXXyNW1bW0GQR1XS
GAMG	M2j0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUiwdXYzUUN3ME2wMlA{PDN3IN88US=>	MVzTRW5ITVJ?
CP50-MEL-B	NYnUSXQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHX5VWJKSzVyPUCuNFM1PSEQvF2=	MYfTRW5ITVJ?
OVCAR-5	NWO1cGZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLJTWM2OD1yLkCzOFgh\|ryP	MWPTRW5ITVJ?
SK-MES-1	NGrGeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vJV2lEPTB;MD6wN\|YxPiEQvF2=	Mme4V2FPT0WU
VM-CUB-1	NXXVTpExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXuTWM2OD1yLkCzOlU4KM7:TR?=	M{PLOHNCVkeHUh?=
WM-115	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLSTWM2OD1yLkCzO\|YzKM7:TR?=	NUXESGp3W0GQR1XS
DSH1	NYjn[WQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3pbJFvUUN3ME2wMlA{QDB5IN88US=>	MmX3V2FPT0WU
Becker	M4DQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vuc2lEPTB;MD6wN\|g5PSEQvF2=	MV7TRW5ITVJ?
SW962	NHz1VnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrVZ214UUN3ME2wMlA{QTR3IN88US=>	MlW0V2FPT0WU
TYK-nu	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTBwMEO5PFUh\|ryP	MoTtV2FPT0WU
HO-1-N-1	M1fZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHj2NpdKSzVyPUCuNFQxOjFizszN	MnnkV2FPT0WU
T98G	MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2[0dmlEPTB;MD6wOFExOyEQvF2=	M{LETnNCVkeHUh?=
ACN	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwMESxOlIh\|ryP	MYjTRW5ITVJ?
SW780	M1eyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTBwMESyNFMh\|ryP	NGD2VJBUSU6JRWK=
Detroit562	M3H1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\vTWM2OD1yLkC0NlM6KM7:TR?=	NFe3VnVUSU6JRWK=
BB49-HNC	NXG0OY9WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XGXWlEPTB;MD6wOFI1OyEQvF2=	M171ZXNCVkeHUh?=
HN	NWLoRpZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vvUWlEPTB;MD6wOFI4OiEQvF2=	M3zFfHNCVkeHUh?=
H9	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwMESzO\|Eh\|ryP	M2jXWnNCVkeHUh?=
VA-ES-BJ	M4DiXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLETWM2OD1yLkC0OFQ4KM7:TR?=	NVPIfGVxW0GQR1XS
MEL-JUSO	NXrQNIdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\xTWM2OD1yLkC0OFc2KM7:TR?=	NEHpc\|hUSU6JRWK=
BT-474	MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrRTWM2OD1yLkC0OUDPxE1?	M4qwOnNCVkeHUh?=
CaR-1	Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkftTWM2OD1yLkC0OVQ6KM7:TR?=	NX;FUmN1W0GQR1XS
PSN1	M1fUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrlXmdKSzVyPUCuNFQ3ODNizszN	M1LjfXNCVkeHUh?=
KYSE-510	Mon5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XJcWlEPTB;MD6wOFY1QSEQvF2=	MV3TRW5ITVJ?
KP-4	M2XT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHsN\|JKSzVyPUCuNFQ4PTNizszN	NVvtfFBxW0GQR1XS
KYSE-410	MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMES3O\|Ih\|ryP	NHX5Z2ZUSU6JRWK=
G-402	M{[yfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jtfmlEPTB;MD6wOFc5QSEQvF2=	M4\YTnNCVkeHUh?=
DOK	MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7iTWM2OD1yLkC0PVAzKM7:TR?=	M1HxS3NCVkeHUh?=
COR-L88	MlLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1n4NmlEPTB;MD6wOFkyOiEQvF2=	NU\NS5Y2W0GQR1XS
SKG-IIIa	NFW1[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLudmhKSzVyPUCuNFQ6QDZizszN	MoruV2FPT0WU
AN3-CA	NVLCb5hmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHxSXJOUUN3ME2wMlA2KM7:TR?=	M1\xPHNCVkeHUh?=
SW48	NEX6SG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXrPWRKSzVyPUCuNFUxOzlizszN	NXjmfohuW0GQR1XS
YKG-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vRTGlEPTB;MD6wOVA4OSEQvF2=	MlvoV2FPT0WU
KYSE-150	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLlTWM2OD1yLkC1NlM2KM7:TR?=	NUL0PXpWW0GQR1XS
HuO-3N1	Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7HfJAyUUN3ME2wMlA2OjN5IN88US=>	MW\TRW5ITVJ?
LB1047-RCC	NGDhc3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3OTWM2OD1yLkC1Nlk3KM7:TR?=	MYXTRW5ITVJ?
NCI-H2030	MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILJb3dKSzVyPUCuNFU1OTRizszN	NWT5Uo1[W0GQR1XS
YH-13	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjhTWM2OD1yLkC1O\|IzKM7:TR?=	M3fScXNCVkeHUh?=
5637	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjSW\|Z2UUN3ME2wMlA2PzRizszN	M{[3TnNCVkeHUh?=
LOXIMVI	NH34WIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mkf2TWM2OD1yLkC1PFczKM7:TR?=	NWTpfIIxW0GQR1XS
GT3TKB	M1HNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrE[phKSzVyPUCuNFU6PDJizszN	MVzTRW5ITVJ?
TCCSUP	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rMUmlEPTB;MD6wOVk3PCEQvF2=	MmnyV2FPT0WU
EPLC-272H	M4LQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nUfWlEPTB;MD6wOlIxPSEQvF2=	MUfTRW5ITVJ?
LU-99A	NX:4VFBrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXQTWM2OD1yLkC2NlM4KM7:TR?=	MXjTRW5ITVJ?
NCI-H1755	NWnyTmVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITScY1KSzVyPUCuNFY{PDFizszN	NHzZSJlUSU6JRWK=
KM12	MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\yTWM2OD1yLkC2N\|Q5KM7:TR?=	NIi3NXNUSU6JRWK=
SF295	M4jkVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PCR2lEPTB;MD6wOlQ2OiEQvF2=	MWjTRW5ITVJ?
MZ2-MEL	NG\lcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;K[nJKSzVyPUCuNFY2PTNizszN	MnPKV2FPT0WU
HEC-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3hTWM2OD1yLkC2OVg5KM7:TR?=	NHHKNplUSU6JRWK=
SW684	NVXyWYhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPqfpdFUUN3ME2wMlA3PTlzIN88US=>	NIPuU29USU6JRWK=
SF539	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnG[WdKSzVyPUCuNFY3QDFizszN	MU\TRW5ITVJ?
GMS-10	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPnTWM2OD1yLkC2Olk6KM7:TR?=	MV\TRW5ITVJ?
MV-4-11	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPEO5lKSzVyPUCuNFY5ODNizszN	M3fWdXNCVkeHUh?=
HT-29	NIDRPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnMcoxKSzVyPUCuNFY6OTlizszN	MmfsV2FPT0WU
23132-87	MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnqem1nUUN3ME2wMlA3QTVizszN	MUnTRW5ITVJ?
SW620	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3q2d2lEPTB;MD6wO\|AzPiEQvF2=	Mnv5V2FPT0WU
HCC1806	NGjic3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPBRW9KSzVyPUCuNFcyOzFizszN	M{j5SXNCVkeHUh?=
Hs-578-T	NEHrNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXflb4NYUUN3ME2wMlA4OjB6IN88US=>	MYfTRW5ITVJ?
A2058	M1;pXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;hV4I1UUN3ME2wMlA4OjJ6IN88US=>	MkjTV2FPT0WU
MEL-HO	Ml[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjlW25zUUN3ME2wMlA4OjV3IN88US=>	M{PRXXNCVkeHUh?=
HCC2998	NVLMPG5ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3noS2lEPTB;MD6wO\|M1PyEQvF2=	MkXOV2FPT0WU
HuO9	NYfld2dPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3HOYY{UUN3ME2wMlA4PTh7IN88US=>	NXTMT401W0GQR1XS
CAL-39	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\ueYZKSzVyPUCuNFc4PjZizszN	M1HHc3NCVkeHUh?=
M14	NVXt[Xk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTBwMEe5NVMh\|ryP	M{XN[HNCVkeHUh?=
BFTC-909	NVfQ[3VIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTBwMEe5Olkh\|ryP	MnvPV2FPT0WU
TE-11	NVvRZo5jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DINmlEPTB;MD6wO\|k6PiEQvF2=	NFHCWGlUSU6JRWK=
TGBC1TKB	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTBwMEiwOFMh\|ryP	NGLBcJFUSU6JRWK=
L-363	NWq4T3NRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwMEiyNFYh\|ryP	M1H5dHNCVkeHUh?=
A431	NV\NcoxFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\1NmlEPTB;MD6wPFIyKM7:TR?=	Mme0V2FPT0WU
MKN45	M2WzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTsOYxGUUN3ME2wMlA5OjF7IN88US=>	MXnTRW5ITVJ?
HT-1080	MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXYPXJyUUN3ME2wMlA5PDN7IN88US=>	M3PqdHNCVkeHUh?=
OVCAR-8	NUHMdWc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX36RXpZUUN3ME2wMlA5PjJ{IN88US=>	MoDnV2FPT0WU
LCLC-97TM1	MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXYeXNKSzVyPUCuNFg4OjhizszN	M1Hi[3NCVkeHUh?=
M059J	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwMEmwNlch\|ryP	M3TONnNCVkeHUh?=
SK-MEL-2	NI\TT4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTBwMEmwOkDPxE1?	MVrTRW5ITVJ?
TE-1	MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DxZWlEPTB;MD6wPVIxPCEQvF2=	NELLUXBUSU6JRWK=
KYSE-180	NIjYRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fMcGlEPTB;MD6wPVI3OiEQvF2=	Mn3XV2FPT0WU
D-247MG	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnCTWM2OD1yLkC5OFU2KM7:TR?=	NHi1bZhUSU6JRWK=
8-MG-BA	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIX0dpdKSzVyPUCuNFk1PzJizszN	MVfTRW5ITVJ?
NCI-H1792	NUe3U2EzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH[4OZhKSzVyPUCuNFk3OThizszN	NYK4WlU4W0GQR1XS
MCF7	NU\sWWM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;QfmlEPTB;MD6wPVY4PyEQvF2=	NHTFdm9USU6JRWK=
NCI-H2122	NIjKN3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{GxOmlEPTB;MD6wPVc1PSEQvF2=	NGXKWmtUSU6JRWK=
EFO-27	MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfncpdKSzVyPUCuNFk6QTdizszN	MYjTRW5ITVJ?
LB2241-RCC	MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zvN2lEPTB;MD6xNFA2PCEQvF2=	NWru[4luW0GQR1XS
SN12C	NUK2OFdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTlTWM2OD1yLkGwNVA4KM7:TR?=	MWLTRW5ITVJ?
A498	NX3mWnJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWm5SG97UUN3ME2wMlExOThizszN	MmrPV2FPT0WU
PANC-03-27	NI\5OmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\yVmlEPTB;MD6xNFI5PiEQvF2=	MlO2V2FPT0WU
NCI-H1581	NELGRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XmXWlEPTB;MD6xNFI6KM7:TR?=	M3Pa[HNCVkeHUh?=
U-87-MG	Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXsSJBKSzVyPUCuNVA{ODdizszN	Mon3V2FPT0WU
G-401	MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\t[\|dKSzVyPUCuNVA{PTNizszN	M3PTXHNCVkeHUh?=
SiHa	M{HxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDTcZNKSzVyPUCuNVA1QDZizszN	M1faOHNCVkeHUh?=
U251	NG\RWHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXKwb\|ZTUUN3ME2wMlExPTJ3IN88US=>	NF\CXmFUSU6JRWK=
MMAC-SF	NYf3c29TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLQUo1KSzVyPUCuNVA2OzFizszN	MYXTRW5ITVJ?
BB65-RCC	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTBwMUC1OVQh\|ryP	NGDLV3BUSU6JRWK=
NKM-1	M162N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDwTWM2OD1yLkGwOlY3KM7:TR?=	M3PHPXNCVkeHUh?=
HD-MY-Z	NEnGTZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rD[WlEPTB;MD6xNFg4OyEQvF2=	MlS4V2FPT0WU
TGBC11TKB	MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXxO5h[UUN3ME2wMlExQTB\|IN88US=>	NFHOOFlUSU6JRWK=
COLO-679	NIfyW\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPCclk3UUN3ME2wMlEyOjFzIN88US=>	MVzTRW5ITVJ?
TE-8	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHpTWM2OD1yLkGxNlY1KM7:TR?=	M3jmVHNCVkeHUh?=
SK-MEL-28	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnK5TWM2OD1yLkGxN\|IyKM7:TR?=	MXvTRW5ITVJ?
SH-4	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnncGVjUUN3ME2wMlEyOzV4IN88US=>	MYnTRW5ITVJ?
KALS-1	NHmwTIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fj[GlEPTB;MD6xNVM6OyEQvF2=	NHL4cGVUSU6JRWK=
RKO	NGf4dFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\ZXIVrUUN3ME2wMlEyPzZ2IN88US=>	M4K5dnNCVkeHUh?=
OMC-1	MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPjTWM2OD1yLkGxO\|k4KM7:TR?=	M1jlRnNCVkeHUh?=
BT-549	NUXMc\|M2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTaTWM2OD1yLkGxO\|k6KM7:TR?=	MV3TRW5ITVJ?
NCI-H28	Ml3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGftOmRKSzVyPUCuNVE5OTdizszN	MWXTRW5ITVJ?
RXF393	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwMUG5PFIh\|ryP	MorxV2FPT0WU
COLO-829	NEHBWJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwMUKwNFUh\|ryP	Ml73V2FPT0WU
HMV-II	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLVTWM2OD1yLkGyNFIh\|ryP	Ml\5V2FPT0WU
SW1990	NXnzN29{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXiXIVLUUN3ME2wMlEzOTV5IN88US=>	MWHTRW5ITVJ?
NCI-H1437	M1W4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHxV5FKSzVyPUCuNVIyPTdizszN	NHzvWI9USU6JRWK=
SNB75	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzKOpdKSzVyPUCuNVIyPjlizszN	MlLoV2FPT0WU
EW-3	NVjDcodpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PldmlEPTB;MD6xNlY3OSEQvF2=	MoD5V2FPT0WU
SAS	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPrW4JjUUN3ME2wMlEzPjlizszN	NH;5b3FUSU6JRWK=
NCI-H1666	NETi[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrSXHFsUUN3ME2wMlEzPzd2IN88US=>	NUH0[FR5W0GQR1XS
A375	NYnYdI9HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jUPGlEPTB;MD6xNlc4QCEQvF2=	MoruV2FPT0WU
CAMA-1	M{PEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13MTGlEPTB;MD6xNlkzPCEQvF2=	M{nnfHNCVkeHUh?=
HuP-T4	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPXZoRKSzVyPUCuNVI6PDNizszN	MmjaV2FPT0WU
NCI-H292	M375Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrUTGdKSzVyPUCuNVMyOSEQvF2=	MoS1V2FPT0WU
PC-14	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHod49TUUN3ME2wMlE{OjFzIN88US=>	NVmxVHdVW0GQR1XS
BPH-1	NVfHUWxsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HodmlEPTB;MD6xN\|QyKM7:TR?=	MkDWV2FPT0WU
GAK	NGjyUHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTBwMUO1Olch\|ryP	NEPZOmNUSU6JRWK=
VMRC-RCZ	M4HufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fiR2lEPTB;MD6xN\|c3OiEQvF2=	Mnz3V2FPT0WU
SK-MEL-24	NF;4bJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLEeItKSzVyPUCuNVM5PyEQvF2=	MVTTRW5ITVJ?
LB831-BLC	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTBwMUO4PFMh\|ryP	M4ex[3NCVkeHUh?=
NCI-H2452	Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHWTWM2OD1yLkGzPVU3KM7:TR?=	NH3PfGZUSU6JRWK=
RT-112	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4S0O2lEPTB;MD6xOFA{PSEQvF2=	NGnt[mFUSU6JRWK=
GP5d	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HkN2lEPTB;MD6xOFExPCEQvF2=	MknYV2FPT0WU
LC-2-ad	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILmeoNKSzVyPUCuNVQyOjFizszN	MVTTRW5ITVJ?
MPP-89	NGX2bXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HIbWlEPTB;MD6xOFEzPSEQvF2=	M2LOOnNCVkeHUh?=
NUGC-3	NGi3OVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmT0TWM2OD1yLkG0OFc5KM7:TR?=	M4PSb3NCVkeHUh?=
GI-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHzOGFKSzVyPUCuNVQ2PThizszN	NUPESI5GW0GQR1XS
HCC1419	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\sTWM2OD1yLkG0OVc3KM7:TR?=	M4PXd3NCVkeHUh?=
SW1573	M37ZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnnTWM2OD1yLkG0O\|U5KM7:TR?=	Ml\vV2FPT0WU
NCI-H2347	NWrpOHN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwMUS4N\|kh\|ryP	Mki1V2FPT0WU
Mewo	NHXic5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1T1bWlEPTB;MD6xOFg5QSEQvF2=	M2DSSnNCVkeHUh?=
639-V	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTBwMUWwNVMh\|ryP	M4\K[3NCVkeHUh?=
AsPC-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnkTWM2OD1yLkG1NlI2KM7:TR?=	NFH6ZYhUSU6JRWK=
NCI-H1648	NXj2UXFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3OxOGlEPTB;MD6xOVI{OiEQvF2=	NHTYW3BUSU6JRWK=
786-0	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2CwVmlEPTB;MD6xOVM5OSEQvF2=	NVnTXZRMW0GQR1XS
ETK-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\POI9KSzVyPUCuNVU6KM7:TR?=	NEXjbGtUSU6JRWK=
BxPC-3	NXTQXIRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTlSVJKSzVyPUCuNVU6PjZizszN	M3nkUHNCVkeHUh?=
CAL-62	NIXVN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTydGRKSzVyPUCuNVYyPjlizszN	NFSwbHBUSU6JRWK=
HCC1937	NVywVXp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWizSWZmUUN3ME2wMlE3Ojd3IN88US=>	MXLTRW5ITVJ?
NCI-H1299	NXvzR2N6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XiPWlEPTB;MD6xOlI5PSEQvF2=	NFLCSVVUSU6JRWK=
SW1088	NEjrfWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfjXFFKSzVyPUCuNVY1OTNizszN	NVLVUGJ2W0GQR1XS
FTC-133	NIDWRmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwMU[1OEDPxE1?	Ml7OV2FPT0WU
OC-314	NWjBWZpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEe3UWdKSzVyPUCuNVY3QSEQvF2=	M{nCWHNCVkeHUh?=
SCC-9	NIHmd\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPOTWM2OD1yLkG2O\|E3KM7:TR?=	MnXEV2FPT0WU
HT-1376	MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrufJpKSzVyPUCuNVY6OzZizszN	NIP0NIZUSU6JRWK=
U-2-OS	NUSzN2MzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmD2TWM2OD1yLkG3NVc{KM7:TR?=	NVHjXZE6W0GQR1XS
COLO-824	NIi0Z5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLEW\|ZKSzVyPUCuNVczQTRizszN	M4LVc3NCVkeHUh?=
BB30-HNC	NEjY[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nxSmlEPTB;MD6xO\|M{KM7:TR?=	MVnTRW5ITVJ?
NCI-H2087	M{DBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnITWM2OD1yLkG3N\|Y5KM7:TR?=	MX7TRW5ITVJ?
NCI-H2170	MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEP0O2FKSzVyPUCuNVc2OzZizszN	MYDTRW5ITVJ?
SK-OV-3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwMUe1O\|Eh\|ryP	NEL1ZmRUSU6JRWK=
MZ7-mel	NF;vUWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjaTWM2OD1yLkG3OlQ6KM7:TR?=	NHrJV4VUSU6JRWK=
NCI-H650	MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXqTWM2OD1yLkG3OlgzKM7:TR?=	MVPTRW5ITVJ?
KOSC-2	MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGH1fGFKSzVyPUCuNVc4OzRizszN	MUXTRW5ITVJ?
SCC-4	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2K5ZWlEPTB;MD6xO\|c4PyEQvF2=	MX7TRW5ITVJ?
MDA-MB-157	NX[5TWMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnsdYFKSzVyPUCuNVgxQDJizszN	MVfTRW5ITVJ?
KYSE-520	NUKxZnJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX70TmJGUUN3ME2wMlE5OiEQvF2=	M3;TOXNCVkeHUh?=
LK-2	NU\ZWlBlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwMUizNFMh\|ryP	NHjvZ5NUSU6JRWK=
KNS-81-FD	M1L1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTBwMUizPVQh\|ryP	M1\1[nNCVkeHUh?=
IGROV-1	NGnpZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTBwMUi0OFMh\|ryP	MWjTRW5ITVJ?
DEL	NX[2[oRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHpTWM2OD1yLkG4OFUh\|ryP	MVnTRW5ITVJ?
NCI-H1395	NEPlcJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmW3TWM2OD1yLkG4OlgzKM7:TR?=	NWDMXFFIW0GQR1XS
JEG-3	MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLYbogxUUN3ME2wMlE5PzB3IN88US=>	M{n6XXNCVkeHUh?=
BCPAP	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHQR\|M4UUN3ME2wMlE5QDd{IN88US=>	MmXrV2FPT0WU
CAL-27	M{OyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTYTWM2OD1yLkG5NFIzKM7:TR?=	NG\UfY5USU6JRWK=
RD	Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml:5TWM2OD1yLkG5NVE{KM7:TR?=	MoPQV2FPT0WU
RVH-421	M{D1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTBwMUmxNVYh\|ryP	NEHkTllUSU6JRWK=
Capan-2	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUD4PFFqUUN3ME2wMlE6OjV4IN88US=>	NH3rbZpUSU6JRWK=
COLO-680N	NYXYZnpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzOTWM2OD1yLkG5N\|Y1KM7:TR?=	NUHLcXFjW0GQR1XS
NCI-H1650	MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn76TWM2OD1yLkKwNFU4KM7:TR?=	NGKxcFJUSU6JRWK=
SBC-5	MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwMkCxNVgh\|ryP	M2rudXNCVkeHUh?=
U031	Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHmRlEyUUN3ME2wMlIxPTR5IN88US=>	MVPTRW5ITVJ?
S-117	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwMkC1OlQh\|ryP	M4XEe3NCVkeHUh?=
DoTc2-4510	NWi0SYJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYq4VYs4UUN3ME2wMlIxPzZ7IN88US=>	M{jkbHNCVkeHUh?=
AM-38	M32xZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXYdlkyUUN3ME2wMlIxQDR6IN88US=>	NGH6dmRUSU6JRWK=
A172	M2exVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rVXWlEPTB;MD6yNVAzOiEQvF2=	NWnHfG9xW0GQR1XS
HPAF-II	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7xdWdKUUN3ME2wMlIyOjZ2IN88US=>	NW\rOFhNW0GQR1XS
769-P	Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofFTWM2OD1yLkKxNlgh\|ryP	Mln1V2FPT0WU
MFE-280	NH\FS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwMkGyPVgh\|ryP	NWq4c3NnW0GQR1XS
TE-9	NInXVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fjSmlEPTB;MD6yNVc5PiEQvF2=	MYfTRW5ITVJ?
C2BBe1	NXj4VphFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXn4dXM3UUN3ME2wMlIzOTlizszN	Mn7xV2FPT0WU
EoL-1-cell	NXnXNYFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorhTWM2OD1yLkKyNlA{KM7:TR?=	MkeyV2FPT0WU
G-361	M120VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELSZVBKSzVyPUCuNlI3QDJizszN	MULTRW5ITVJ?
KYSE-270	M2DufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwMkOwPFQh\|ryP	MUHTRW5ITVJ?
TK10	NY[2NmxvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmq3TWM2OD1yLkKzNVE4KM7:TR?=	Mlq0V2FPT0WU
ML-2	MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwMkOxNVkh\|ryP	NIL2dJZUSU6JRWK=
MHH-ES-1	Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTBwMkO2PFEh\|ryP	NWe4NXVXW0GQR1XS
BHY	NYDMWlZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGi3UoZKSzVyPUCuNlM3QTFizszN	M1H3OnNCVkeHUh?=
LS-513	NXLsfWFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHYTWM2OD1yLkKzPVYyKM7:TR?=	NX3uOIZ6W0GQR1XS
COLO-678	M1ewWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7BV4RKSzVyPUCuNlQxPDRizszN	Mo\FV2FPT0WU
NCI-H747	MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3uT5RtUUN3ME2wMlI1OTZ7IN88US=>	MXnTRW5ITVJ?
K5	Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY[1XJN7UUN3ME2wMlI1OzhizszN	M3nMUHNCVkeHUh?=
OS-RC-2	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoToTWM2OD1yLkK0OVA6KM7:TR?=	MV7TRW5ITVJ?
KINGS-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPnb4JKSzVyPUCuNlQ2OjlizszN	M4nVSnNCVkeHUh?=
SCC-25	Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmP6TWM2OD1yLkK0OVY{KM7:TR?=	NILQSWZUSU6JRWK=
CAPAN-1	NWS1boU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{SxZWlEPTB;MD6yOFc5OyEQvF2=	M1\EUHNCVkeHUh?=
ESS-1	MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NESzN45KSzVyPUCuNlQ5ODVizszN	NFjwOlBUSU6JRWK=
TE-6	NH;XdYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LMT2lEPTB;MD6yOVc2KM7:TR?=	MoHnV2FPT0WU
LB2518-MEL	NFPlS5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfJTWM2OD1yLkK1O\|c4KM7:TR?=	NGnLU49USU6JRWK=
COLO-800	NVTFTIZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMkW4NVIh\|ryP	M2S3THNCVkeHUh?=
LU-134-A	NX3WflV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHiTWM2OD1yLkK2NVM3KM7:TR?=	M3fMOXNCVkeHUh?=
NCI-H1155	MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fJUGlEPTB;MD6yOlE3OiEQvF2=	NVHLNY81W0GQR1XS
MFM-223	NV;NcZNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkD3TWM2OD1yLkK2N\|Y{KM7:TR?=	NXu1S29lW0GQR1XS
HTC-C3	MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYO5UGg5UUN3ME2wMlI3PTB4IN88US=>	NHjKZ3BUSU6JRWK=
HCT-116	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jSbmlEPTB;MD6yOlU6QSEQvF2=	MnOzV2FPT0WU
Ca-Ski	NGrXR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTBwMk[2O\|gh\|ryP	NXnKe5dKW0GQR1XS
SBC-1	NH\3OphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPkOFNKSzVyPUCuNlY4PDJizszN	Mn7zV2FPT0WU
NB69	NETzdJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFOyTmRKSzVyPUCuNlcxQDdizszN	MVTTRW5ITVJ?
J82	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrsc\|RnUUN3ME2wMlI4OjZ3IN88US=>	MVLTRW5ITVJ?
U-118-MG	NWTXTIFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTBwMke1O\|kh\|ryP	Mk\1V2FPT0WU
NCI-H1355	NUXoeWxDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlGwTWM2OD1yLkK4NFc1KM7:TR?=	MWfTRW5ITVJ?
NCI-H1048	M2PnbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrkUXozUUN3ME2wMlI5QTV4IN88US=>	NInWPJVUSU6JRWK=
SW954	NEP2Vo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fD[2lEPTB;MD6yPVIzPyEQvF2=	Mo\hV2FPT0WU
NMC-G1	MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjad3RPUUN3ME2wMlI6Ojd5IN88US=>	M2DhO3NCVkeHUh?=
SW1710	M1THUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzHTWM2OD1yLkK5OFk1KM7:TR?=	NHLKdFdUSU6JRWK=
KY821	MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;EfmdKSzVyPUCuNlk5PzJizszN	NW\o[\|RWW0GQR1XS
HCC38	NUTQZ\|VJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PIR2lEPTB;MD6zNFA4QCEQvF2=	NWTXOHJuW0GQR1XS
NCI-SNU-5	NX7wW2JpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jOTmlEPTB;MD6zNFU1KM7:TR?=	NWL3UpRsW0GQR1XS
ES8	Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTBwM{C3PFQh\|ryP	MYDTRW5ITVJ?
COLO-792	NXi4VYY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXS2cWVmUUN3ME2wMlMyOjVzIN88US=>	M1PhPHNCVkeHUh?=
BFTC-905	NUfXSnFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PvUmlEPTB;MD6zNVUzOSEQvF2=	MYfTRW5ITVJ?
ChaGo-K-1	NEjwRW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTBwM{G3NVUh\|ryP	NWnmb4lnW0GQR1XS
Daoy	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoCzTWM2OD1yLkOxO\|I{KM7:TR?=	M3HiNnNCVkeHUh?=
SJSA-1	NWrlboFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPYTWM2OD1yLkOxPFQ4KM7:TR?=	MVPTRW5ITVJ?
KNS-62	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmW0TWM2OD1yLkOyNFg5KM7:TR?=	MWDTRW5ITVJ?
CAKI-1	MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHSS4JKSzVyPUCuN\|IyOTFizszN	MX\TRW5ITVJ?
UACC-62	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTBwM{KyNlch\|ryP	NUfxdGRCW0GQR1XS
HuCCT1	M4fEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDSfZpKSzVyPUCuN\|IzQDNizszN	NEXzVG5USU6JRWK=
CTB-1	NEKxTphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPHTWM2OD1yLkOyO\|U{KM7:TR?=	NVHpOmhsW0GQR1XS
NTERA-S-cl-D1	Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwM{K4N\|Yh\|ryP	MYDTRW5ITVJ?
T-24	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGewPW9KSzVyPUCuN\|MyPTlizszN	NY\rZ4xHW0GQR1XS
KYSE-70	M1HjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TOSGlEPTB;MD6zN\|I5OyEQvF2=	NU[zUnVZW0GQR1XS
SW626	M1nUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3uXZJ6UUN3ME2wMlM{PTN{IN88US=>	MYnTRW5ITVJ?
LB996-RCC	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2D0cGlEPTB;MD6zN\|YyQSEQvF2=	MVPTRW5ITVJ?
DMS-273	Ml3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17T[GlEPTB;MD6zN\|kyPiEQvF2=	M1zJXXNCVkeHUh?=
SW1783	Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37YZWlEPTB;MD6zN\|k6PyEQvF2=	MVvTRW5ITVJ?
KU812	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DLO2lEPTB;MD6zOFA{QCEQvF2=	M3H1b3NCVkeHUh?=
HSC-2	NYPJc3dDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moq3TWM2OD1yLkO0NFU{KM7:TR?=	NYfZbFdOW0GQR1XS
A3-KAW	MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\XOHVmUUN3ME2wMlM1OTZ{IN88US=>	Mme5V2FPT0WU
COLO-684	NGjHWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwM{S1NFEh\|ryP	NXnweY9TW0GQR1XS
NCI-H2405	NIfaXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\vXpR5UUN3ME2wMlM1PjNzIN88US=>	NH\xRmZUSU6JRWK=
NCI-H2228	NUXad4ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWn1XmVFUUN3ME2wMlM2OzV5IN88US=>	MoO4V2FPT0WU
NB13	M3LTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\jcmhKSzVyPUCuN\|Y5OjlizszN	NYO3Z4ZGW0GQR1XS
no-11	NWjUc3hlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETCUnBKSzVyPUCuN\|Y6PSEQvF2=	MUnTRW5ITVJ?
DK-MG	MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLGTWM2OD1yLkO3NVg5KM7:TR?=	MXrTRW5ITVJ?
NBsusSR	M372SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPkOXBKSzVyPUCuN\|czQDVizszN	Ml\zV2FPT0WU
KP-N-YS	NVraXFhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfvelFsUUN3ME2wMlM4PDZ\|IN88US=>	NIfzWodUSU6JRWK=
CFPAC-1	NXTEWVg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTBwM{e1NVgh\|ryP	MXjTRW5ITVJ?
KARPAS-45	M4HiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{SxTGlEPTB;MD6zO\|g3OiEQvF2=	MU\TRW5ITVJ?
NCI-H1793	M4KweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoezTWM2OD1yLkO4OVEh\|ryP	NHXuTJNUSU6JRWK=
HCE-T	MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTBwM{i2NFMh\|ryP	MoTKV2FPT0WU
NCI-H520	Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;HS\|JKSzVyPUCuN\|g4ODNizszN	M3rKbnNCVkeHUh?=
HCC2157	M4HpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4DUSGlEPTB;MD6zPFc5OSEQvF2=	MlPmV2FPT0WU
EW-18	NEn4T5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTBwM{i5OFEh\|ryP	NGn6N3hUSU6JRWK=
RO82-W-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3G2UmlEPTB;MD6zPVY6QSEQvF2=	MXrTRW5ITVJ?
HuP-T3	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;xdmlEPTB;MD60NFE1OyEQvF2=	MUPTRW5ITVJ?
PANC-10-05	M3yzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\5UVE5UUN3ME2wMlQyOTdizszN	M2TtT3NCVkeHUh?=
NCI-H1703	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXeyc5lQUUN3ME2wMlQyPDR4IN88US=>	NETQNW1USU6JRWK=
TE-10	M1\zUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknyTWM2OD1yLkSxOFQ4KM7:TR?=	NHKzTm9USU6JRWK=
HOS	M{LsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTBwNEG2PFIh\|ryP	MkjiV2FPT0WU
LN-405	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTBwNEG2PFch\|ryP	MkPYV2FPT0WU
A427	M1Hi[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTBwNEG5PFEh\|ryP	NUPyUHFSW0GQR1XS
CAL-12T	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3tXIxKSzVyPUCuOFI4QCEQvF2=	NGLOepdUSU6JRWK=
SW756	NIDYXllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXu3VW5bUUN3ME2wMlQ1OTh\|IN88US=>	M3XEOHNCVkeHUh?=
YAPC	NX7Ie\|liT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2naUWlEPTB;MD60OVA5KM7:TR?=	M1\zS3NCVkeHUh?=
GOTO	NEH4Xm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTBwNEWxOkDPxE1?	MVnTRW5ITVJ?
C3A	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInj[lJKSzVyPUCuOFU1OzdizszN	NF:1bpdUSU6JRWK=
UM-UC-3	MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XxTmlEPTB;MD60OVQ4KM7:TR?=	MXPTRW5ITVJ?
NCI-H1573	NGXzUnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nLPGlEPTB;MD60OVU3QSEQvF2=	M{\0dnNCVkeHUh?=
LS-411N	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnEc5doUUN3ME2wMlQ3PTJ5IN88US=>	M3;vWXNCVkeHUh?=
COR-L23	NE\GUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDLOHoxUUN3ME2wMlQ3PzZ2IN88US=>	MU\TRW5ITVJ?
HCE-4	Mki2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzFcoJKSzVyPUCuOFc1PDZizszN	M1;YR3NCVkeHUh?=
NCI-H2291	NWTHdYFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HzVWlEPTB;MD60O\|g6PiEQvF2=	MXLTRW5ITVJ?
A101D	M3n6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYP0U2JyUUN3ME2wMlQ5ODV\|IN88US=>	MYnTRW5ITVJ?
HT-3	NFrIWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7GTWM2OD1yLkS4NlE4KM7:TR?=	MlfEV2FPT0WU
HOP-62	Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml:xTWM2OD1yLkS5PFY2KM7:TR?=	NHnTUWpUSU6JRWK=
PC-3	NXPuO3hbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnMTWM2OD1yLkWxOVA4KM7:TR?=	NUjESFJEW0GQR1XS
CTV-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nM[WlEPTB;MD61NlY3QSEQvF2=	M2[x[nNCVkeHUh?=
PANC-08-13	Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXn4UJdKUUN3ME2wMlU{OTd5IN88US=>	MYLTRW5ITVJ?
CAL-120	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jrbWlEPTB;MD61N\|M6QSEQvF2=	MVTTRW5ITVJ?
UMC-11	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHtTWM2OD1yLkW1NlM1KM7:TR?=	M{\JPHNCVkeHUh?=
MSTO-211H	MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nJXWlEPTB;MD61OVc3OiEQvF2=	MVrTRW5ITVJ?
NCI-H2126	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjXVY9KSzVyPUCuOVY5OTVizszN	NGfVSmpUSU6JRWK=
SNU-C2B	M4\FbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWO0XmpSUUN3ME2wMlU4QTd5IN88US=>	MYLTRW5ITVJ?
DBTRG-05MG	NIrHRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrFe2ZKSzVyPUCuOVgxPTNizszN	MknnV2FPT0WU
MKN1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYn0WmFYUUN3ME2wMlU5Pzh\|IN88US=>	NEDlbWpUSU6JRWK=
ES3	M1XJfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTBwNUmxNlQh\|ryP	M{\kUHNCVkeHUh?=
OVCAR-3	MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LJT2lEPTB;MD61PVM1OSEQvF2=	M2HObnNCVkeHUh?=
ACHN	M3jxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTBwNkC1Olkh\|ryP	NY\NR2x5W0GQR1XS
SW872	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoOyTWM2OD1yLk[wO\|Y{KM7:TR?=	MnfYV2FPT0WU
CP66-MEL	Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rQdmlEPTB;MD62NFk3QSEQvF2=	MWjTRW5ITVJ?
NCI-H661	MlHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTIeHFiUUN3ME2wMlYyOTB2IN88US=>	MXnTRW5ITVJ?
UACC-893	M{C3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zvemlEPTB;MD62N\|Y5OSEQvF2=	MX\TRW5ITVJ?
JVM-3	Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwNkO4NFQh\|ryP	M17XUXNCVkeHUh?=
SF268	NHK3PVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTkOW5vUUN3ME2wMlY1OzR7IN88US=>	M{nrZnNCVkeHUh?=
OCI-AML2	M4nyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\JfmlEPTB;MD62OVM6PyEQvF2=	NGrwNmpUSU6JRWK=
RPMI-8226	NImzdVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTMTWM2OD1yLk[2N\|I{KM7:TR?=	NFrPZYJUSU6JRWK=
MKN28	MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGG2NlFKSzVyPUCuOlY3OjRizszN	NXnuNIt[W0GQR1XS
MDA-MB-453	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwNkexPEDPxE1?	M3f6enNCVkeHUh?=
BV-173	NWHmfnM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\CeYtKSzVyPUCuOlg3PzlizszN	NHTRdZVUSU6JRWK=
NCI-H358	M13TXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\WTWM2OD1yLk[4O\|I3KM7:TR?=	NYPhOmVxW0GQR1XS
NCI-H1651	M4DPbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PMe2lEPTB;MD63JO69VQ>?	MV;TRW5ITVJ?
MDA-MB-415	NWC1N\|J5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTBwN{C4Nlkh\|ryP	NXWwZY1rW0GQR1XS
8305C	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHH0bm9KSzVyPUCuO\|I1QThizszN	MofiV2FPT0WU
EFM-19	NEDSe4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HDfWlEPTB;MD63N\|Y4OSEQvF2=	M{DwN3NCVkeHUh?=
RERF-LC-MS	M4ftV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTabmFKSzVyPUCuO\|Q3OTNizszN	NHroOpNUSU6JRWK=
A388	NUTZR2NYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTuPYNKUUN3ME2wMlc3PDZ5IN88US=>	NUKzRlBZW0GQR1XS
GI-ME-N	NYDhSXRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULGfoJlUUN3ME2wMlc4OjN3IN88US=>	NUPObldLW0GQR1XS
IGR-1	MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HmW2lEPTB;MD63PVA1OyEQvF2=	M{Lib3NCVkeHUh?=
LNCaP-Clone-FGC	NFXPXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwOECwNFQh\|ryP	M4DqbHNCVkeHUh?=
SK-MEL-3	M{\Ofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTMeVVKSzVyPUCuPFE2ODhizszN	MUjTRW5ITVJ?
UACC-257	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHXTmJMUUN3ME2wMlgzOjNzIN88US=>	MV;TRW5ITVJ?
OE33	NYfSeHVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHlTlRtUUN3ME2wMlg2OTBzIN88US=>	MXnTRW5ITVJ?
QIMR-WIL	NHPJV\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnGTWM2OD1yLki1NVQyKM7:TR?=	NF3YN\|BUSU6JRWK=
NCI-H2009	NUGxbY85T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPETWM2OD1yLki1N\|EyKM7:TR?=	MXXTRW5ITVJ?
NCI-H522	NY\w[2tvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfDTWM2OD1yLki3O\|g{KM7:TR?=	NVLLSFUxW0GQR1XS
Saos-2	NVvEWohmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrKTWM2OD1yLki3PFcyKM7:TR?=	MUDTRW5ITVJ?
NB17	NF3zXHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\yUWlEPTB;MD64PFAzPSEQvF2=	NHf6VHJUSU6JRWK=
D-392MG	NWq4Rm1tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonVTWM2OD1yLki5N\|U3KM7:TR?=	NW\lWJVmW0GQR1XS
SHP-77	M4LQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGH0eopKSzVyPUCuPVA1QDVizszN	MUjTRW5ITVJ?
SK-MEL-30	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVT2OWc3UUN3ME2wMlkyOTh3IN88US=>	M13Zd3NCVkeHUh?=
GCIY	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DWWGlEPTB;MD65NVg1OyEQvF2=	MXnTRW5ITVJ?
HCC70	NF[1eolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\JfWlEPTB;MD65NlA2QSEQvF2=	MYTTRW5ITVJ?
LU-65	M2LzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwOUK1PVEh\|ryP	MoPOV2FPT0WU
NCI-H1563	NXrjVY9nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTBwOUS4OlUh\|ryP	MkXIV2FPT0WU
KURAMOCHI	MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwOUWxPVIh\|ryP	MnPSV2FPT0WU
PA-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXnTWM2OD1yLkm1OFI1KM7:TR?=	NX\JWVJrW0GQR1XS
NOS-1	M4Gxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1e5fmlEPTB;MD65O\|Q5QSEQvF2=	MkLZV2FPT0WU
NCI-H69	NVHDRoVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTBwOUe2N\|Qh\|ryP	MWnTRW5ITVJ?
KYSE-450	NVzKOYt7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XRR2lEPTB;MD65PFYzPiEQvF2=	MVjTRW5ITVJ?
8505C	NWPpVVFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTBwOUm5PFIh\|ryP	NGXwelNUSU6JRWK=
TGBC24TKB	MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTFwMECwPFQh\|ryP	M3j1RXNCVkeHUh?=
PFSK-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTkTWM2OD1zLkCxOFI5KM7:TR?=	NEfvWoxUSU6JRWK=
EKVX	MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTFwMEOxNlEh\|ryP	NVW4dnRSW0GQR1XS
RCM-1	NY\DbIpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTFwMEW1NFch\|ryP	NXjiUnF2W0GQR1XS
SW900	MnjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUC4VphCUUN3ME2xMlA4QDNizszN	NV;TR5RnW0GQR1XS
D-542MG	NFT2cYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITueXJKSzVyPUGuNFc5PTVizszN	NUD6fIlVW0GQR1XS
SK-PN-DW	M33GSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDxSZJKSzVyPUGuNVAxPTZizszN	MnP1V2FPT0WU
NCI-H727	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTFwMUCxOVQh\|ryP	MW\TRW5ITVJ?
SW837	Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{CyUGlEPTB;MT6xNFk2PCEQvF2=	MYjTRW5ITVJ?
BT-20	MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XyO2lEPTB;MT6xNVIxPCEQvF2=	MlP2V2FPT0WU
RH-18	MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFS1e4tKSzVyPUGuNVMyODNizszN	MkD0V2FPT0WU
TE-12	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2S3fmlEPTB;MT6xN\|M{OyEQvF2=	NX;US3hRW0GQR1XS
NB10	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTFwMUOzOFQh\|ryP	M2nBcHNCVkeHUh?=
AU565	NX;INnJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTFwMUW5O\|Mh\|ryP	M{nCSHNCVkeHUh?=
OAW-42	NE[zcWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH2xcnRKSzVyPUGuNVg{ODZizszN	NFjtZo9USU6JRWK=
DJM-1	M{DjWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvQXW1OUUN3ME2xMlE6QDhzIN88US=>	MV;TRW5ITVJ?
HH	M{PXfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jEbmlEPTB;MT6yN\|g{OSEQvF2=	NXTUNHdMW0GQR1XS
LAMA-84	M{XTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTFwMkezPVQh\|ryP	NWrNVnV4W0GQR1XS
KNS-42	M3\NdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfHSWRiUUN3ME2xMlMxOjl4IN88US=>	MkDNV2FPT0WU
NCI-H2052	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLTXJFKSzVyPUGuN\|A2ODdizszN	MWPTRW5ITVJ?
MLMA	NITRXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTFwM{K0NFch\|ryP	M3jBbnNCVkeHUh?=
NB12	M2XUTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\iTWM2OD1zLkO1OlM3KM7:TR?=	M1jkVHNCVkeHUh?=
NCI-H1838	M1fWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;UcWlEPTB;MT6zOlMxPiEQvF2=	NE\2U\|JUSU6JRWK=
NCI-H526	NFTpTFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPTb4xJUUN3ME2xMlM4QDV\|IN88US=>	MnTzV2FPT0WU
LS-123	NXjKOGtlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrWfY12UUN3ME2xMlM6ODl2IN88US=>	Ml74V2FPT0WU
HDLM-2	M3vkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTFwM{myO\|Eh\|ryP	NFT5R2lUSU6JRWK=
MC-IXC	M{PuT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3TUldoUUN3ME2xMlQzOzdzIN88US=>	MX;TRW5ITVJ?
HCT-15	NHT6XJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;ERoRKSzVyPUGuOFMxPjhizszN	NIX3e\|BUSU6JRWK=
NCI-H596	NFXuRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrQU2ZiUUN3ME2xMlQ2ODZzIN88US=>	NIjGTppUSU6JRWK=
ZR-75-30	NGS5VmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULIU2NOUUN3ME2xMlQ4ODh{IN88US=>	MlnJV2FPT0WU
A704	M3\Ed2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTFwNk[1OlMh\|ryP	NGPITWpUSU6JRWK=
OVCAR-4	NV\MelNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3P5ZmlEPTB;MT62PVYxPyEQvF2=	MXjTRW5ITVJ?
SW1417	NEfIOItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXlTWM2OD1zLkeyPFQ6KM7:TR?=	M13XbnNCVkeHUh?=
CAS-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1r2TGlEPTB;MT63N\|k{PiEQvF2=	MX;TRW5ITVJ?
IST-SL1	M1\QSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXj[\|d[UUN3ME2xMlc6PzV7IN88US=>	NGTPW2VUSU6JRWK=
A253	NEPqPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvPTWM2OD1zLkiyNlM6KM7:TR?=	NVfG[WZFW0GQR1XS
EW-16	NVPJV3RnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfDVopKSzVyPUGuPFI5PzVizszN	Mmr0V2FPT0WU
SK-NEP-1	MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LHVGlEPTB;MT64Olk5QCEQvF2=	NYLqZ4R1W0GQR1XS
NCI-H226	M2K2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHKSmZKSzVyPUGuPFk{PTlizszN	Mli0V2FPT0WU
HOP-92	NH35NHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2Pp[WlEPTB;MT65OlA6QSEQvF2=	Mnu4V2FPT0WU
NCI-H441	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPPO5pKSzVyPUKuNFI{OzdizszN	NXXxNZZpW0GQR1XS
LU-139	Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTJwMEOxNVQh\|ryP	M{m3OHNCVkeHUh?=
SJRH30	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzCT4ZvUUN3ME2yMlA1OjV\|IN88US=>	MlPUV2FPT0WU
MG-63	Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33TfmlEPTB;Mj6xOFEyOSEQvF2=	NVK4O3IxW0GQR1XS
NH-12	MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTJwMUWwNFYh\|ryP	MYHTRW5ITVJ?
NB7	MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLlTWM2OD1{LkG5Olc{KM7:TR?=	MXnTRW5ITVJ?
LB771-HNC	NU[3W3VZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILKZ4ZKSzVyPUKuNlA2QTVizszN	M3HHcHNCVkeHUh?=
HCC1569	MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1KyOmlEPTB;Mj6yOFU5OyEQvF2=	NH;JXmFUSU6JRWK=
D-283MED	M2HGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NITCSGVKSzVyPUKuNlQ4QDJizszN	MVLTRW5ITVJ?
J-RT3-T3-5	M4foeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfqZoVKSzVyPUKuNlU{PTFizszN	M1rTZnNCVkeHUh?=
ATN-1	M2e3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmW3TWM2OD1{LkOzNFgzKM7:TR?=	NILWcVBUSU6JRWK=
HCC1954	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXDd2RVUUN3ME2yMlM1PDB6IN88US=>	MVvTRW5ITVJ?
SCC-15	M1\tXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rpWmlEPTB;Mj6zPVMyOiEQvF2=	NGLPOG1USU6JRWK=
COLO-668	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUKwdVR1UUN3ME2yMlQ{OiEQvF2=	MmPIV2FPT0WU
LB373-MEL-D	MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTJwNUS2O\|ch\|ryP	NILmb4xUSU6JRWK=
no-10	MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTnbJRKSzVyPUKuOVQ6PDdizszN	NWW4UI1kW0GQR1XS
HT-1197	MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzkTWM2OD1{Lk[zNVg5KM7:TR?=	NG\ScHRUSU6JRWK=
DU-145	M1jJVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXGXphKSzVyPUKuO\|kyPjJizszN	MmTSV2FPT0WU
SK-N-AS	NX36UZdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml21TWM2OD1{Lki0OlkzKM7:TR?=	NXrPO5hlW0GQR1XS
MOLT-4	MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFK5eGxKSzVyPUKuPFU{OjJizszN	MYXTRW5ITVJ?
EW-22	M1XPXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV63OZpLUUN3ME2yMlkzQDRzIN88US=>	M{C0S3NCVkeHUh?=
DB	NXvsZ4hoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHWyU4JKSzVyPUKuPVc4PTlizszN	NHvXfVVUSU6JRWK=
HL-60	NU\Xb2Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTNwMESzO\|Yh\|ryP	NHLjeJdUSU6JRWK=
SK-N-DZ	MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrsSWtbUUN3ME2zMlA2ODd3IN88US=>	NHPEc5JUSU6JRWK=
NY	MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoKwTWM2OD1\|LkC4OVQzKM7:TR?=	M3:xdnNCVkeHUh?=
T47D	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTNwMUC1OVgh\|ryP	NH\wT2pUSU6JRWK=
NCI-H2029	NHnlS5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHUSJVKSzVyPUOuNlI1PzdizszN	MVTTRW5ITVJ?
KARPAS-299	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfDTWM2OD1\|LkK2NFI4KM7:TR?=	MlTXV2FPT0WU
KM-H2	NWrDZpB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTR[3ZvUUN3ME2zMlMxPjhizszN	NWnNTYlvW0GQR1XS
CHP-134	NI\PO3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nJbmlEPTB;Mz60O\|M6KM7:TR?=	Mm\FV2FPT0WU
22RV1	MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfwTWM2OD1\|LkS5NVY5KM7:TR?=	NWS0eZZNW0GQR1XS
NB5	NGXVOWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILDXZpKSzVyPUOuOVA3QDlizszN	MmTKV2FPT0WU
CW-2	MkHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPYVFNbUUN3ME2zMlU2OzF2IN88US=>	MXzTRW5ITVJ?
EFO-21	NUDicGdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnoTWM2OD1\|LkW2PVQh\|ryP	NVz1[FRHW0GQR1XS
HuH-7	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXp[olKSzVyPUOuOVg1OTRizszN	M12xb3NCVkeHUh?=
ALL-PO	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\uUXJCUUN3ME2zMlYzOzN3IN88US=>	MlLsV2FPT0WU
EM-2	NWDPW5RxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvLUIEyUUN3ME2zMlY6ODFzIN88US=>	MkDKV2FPT0WU
KLE	NITkWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mli3TWM2OD1\|LkezNFI6KM7:TR?=	M2X0bHNCVkeHUh?=
NEC8	NHXMTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPqSXBKSzVyPUOuPVE5ODhizszN	NUDuTJJoW0GQR1XS
KP-N-YN	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTNwOUO0O\|Yh\|ryP	NYX2eZdKW0GQR1XS
SK-MEL-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1f3TGlEPTB;ND6wN\|UyQCEQvF2=	MUfTRW5ITVJ?
CAL-54	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17SWmlEPTB;ND6wOVkyKM7:TR?=	MU\TRW5ITVJ?
MS-1	M4PENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7R[ZBKSzVyPUSuNVYyPTVizszN	NIXFbWhUSU6JRWK=
NCI-H209	NHfDXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NImydnJKSzVyPUSuNlk6QTlizszN	MlnYV2FPT0WU
NOMO-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTRwM{KxN\|Eh\|ryP	M3KwRnNCVkeHUh?=
RPMI-2650	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvtTWM2OD12LkO2N\|I4KM7:TR?=	NXv6WWVbW0GQR1XS
NCI-H810	MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTRwM{m3N\|Yh\|ryP	MoG2V2FPT0WU
Ca9-22	NEjYO\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnjZY9KSzVyPUSuOFU3QTFizszN	M4fhV3NCVkeHUh?=
ES4	M{nSSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoG4TWM2OD12LkS3NFk2KM7:TR?=	M1T5enNCVkeHUh?=
ES6	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2e2[GlEPTB;ND60PVY2PyEQvF2=	Mmn3V2FPT0WU
DMS-114	NG\TOJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTRwNUS2PVEh\|ryP	NFv5dVVUSU6JRWK=
ONS-76	NEj2[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTRwNUe5OUDPxE1?	NUnGZXFsW0GQR1XS
K-562	MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLrTWM2OD12LkezPFE1KM7:TR?=	MXPTRW5ITVJ?
MHH-NB-11	M4O4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXmweVdNUUN3ME20Mlc2PDZzIN88US=>	M1PQfnNCVkeHUh?=
Calu-3	M4PJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTRwN{i1OFgh\|ryP	NYfhN2hXW0GQR1XS
HT55	NWm3cpo1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTqb2RKSzVyPUSuPFQ2PDVizszN	MUHTRW5ITVJ?
SK-N-FI	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlr6TWM2OD12Lki1NFA6KM7:TR?=	NVvvToFvW0GQR1XS
ES1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mny1TWM2OD12Lki2NFU4KM7:TR?=	Ml:wV2FPT0WU
SF126	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\zeFRKSzVyPUSuPVMyQDRizszN	NVrXfXlOW0GQR1XS
ES5	NVzZdIFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrtNJZKSzVyPUWuNVI1OjdizszN	NYTiO2dWW0GQR1XS
LoVo	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXNTWM2OD13LkG1PFcyKM7:TR?=	NILUSVNUSU6JRWK=
SNU-387	NVGyUWprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTVwM{KzN\|kh\|ryP	MoP3V2FPT0WU
C8166	NWfiT5d2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fqO2lEPTB;NT6zOlM{QSEQvF2=	NFnW[ZdUSU6JRWK=
LS-1034	MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTVwNEKzNFch\|ryP	M3Hm[nNCVkeHUh?=
GR-ST	M3;JW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGCyNZhKSzVyPUWuOVIzODFizszN	NVj6RnVZW0GQR1XS
NCI-H1092	MlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIG4SGtKSzVyPUWuO\|I5PDNizszN	NHnTUJVUSU6JRWK=
647-V	NH;5XVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfGTWM2OD13Lke0O\|A3KM7:TR?=	NHnJOGdUSU6JRWK=
EW-13	NXftNlk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlGyTWM2OD13Lke2OlI4KM7:TR?=	Ml\vV2FPT0WU
KGN	M4W0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3KcI1JUUN3ME22MlA6QTJzIN88US=>	MmrDV2FPT0WU
D-423MG	NUPleGdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jE[WlEPTB;Nj60NFI5PCEQvF2=	NWC1eXZSW0GQR1XS
ECC10	NYfGPFF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTdwMUCxNFEh\|ryP	M{\oPHNCVkeHUh?=
TE-5	MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TSfGlEPTB;Nz60NVI6QCEQvF2=	NUPvToJwW0GQR1XS
P12-ICHIKAWA	NUPVOm9UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTdwNEW1NlMh\|ryP	NIqyeZJUSU6JRWK=
NCI-H82	NHjhO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfVTWM2OD15LkS1O\|AyKM7:TR?=	NGHmSYJUSU6JRWK=
NCI-H1993	M{PXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHm1[mtKSzVyPUeuPFMxPjNizszN	NFPScZNUSU6JRWK=
RH-1	M1n2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TxW2lEPTB;Nz64OVI1PCEQvF2=	NIPvTWtUSU6JRWK=
SW948	M37sXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTdwOU[wOFkh\|ryP	NFHzfoNUSU6JRWK=
CAL-33	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTQdWtKSzVyPUeuPVk6OzhizszN	Mmi2V2FPT0WU
U-266	NXv2XXJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHRdZFmUUN3ME24MlE2Pzd5IN88US=>	MUXTRW5ITVJ?
CAL-72	NFrPfXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjw[npKSzVyPUiuNlA{OiEQvF2=	MmjzV2FPT0WU
SNU-423	MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTlwM{[2OlYh\|ryP	NVHkfmpJW0GQR1XS
KG-1	NV3MVJFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fn[WlEPTB;OT61PFQ2PiEQvF2=	MYfTRW5ITVJ?
HCC1395	M1rwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPXTWM2OD17LkmyN\|UzKM7:TR?=	M2nzfXNCVkeHUh?=
BE-13	NF;lSGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTFyLki4PVIh\|ryP	MnmyV2FPT0WU
MKN7	Ml:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDySWlnUUN3ME2xNE46PzZ3IN88US=>	M2\m[nNCVkeHUh?=
697	NXLGNolUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTpTWM2OD1zMT6xOFczKM7:TR?=	NFvsbnBUSU6JRWK=
LU-135	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TFUWlEPTB;MUGuNlMxPyEQvF2=	NX25eHU{W0GQR1XS
ES7	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYj1TGlRUUN3ME2xNU4{OzF\|IN88US=>	MoPHV2FPT0WU
SK-HEP-1	NI\qWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF23fWdKSzVyPUGxMlc3PDZizszN	MkGyV2FPT0WU
BEN	MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2W1TmlEPTB;MUGuPFUyKM7:TR?=	MV7TRW5ITVJ?
NCI-H1770	NIDwbW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjYeHVKSzVyPUGyMlEzPiEQvF2=	MXLTRW5ITVJ?
SW13	NEjESGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrOOllKSzVyPUGyMlE2PDFizszN	NVzzS5Y4W0GQR1XS
MZ1-PC	NUf6bJhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTF{LkW0OVIh\|ryP	MnS2V2FPT0WU
Mo-T	MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlf1TWM2OD1zMj63OFIyKM7:TR?=	NHzHcmJUSU6JRWK=
HLE	NFniW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jp[WlEPTB;MUKuPFIyPSEQvF2=	Mo\YV2FPT0WU
RCC10RGB	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPwXlB4UUN3ME2xN{43PzFizszN	M3PT[nNCVkeHUh?=
COLO-320-HSR	NVfaXmNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NET5bJRKSzVyPUGzMlc{QDFizszN	M3LnNHNCVkeHUh?=
BHT-101	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTF\|LkizOFUh\|ryP	MmK0V2FPT0WU
OCUB-M	MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHze\|k3UUN3ME2xOE4yPjB{IN88US=>	M{e4fXNCVkeHUh?=
MEG-01	NVTCXnVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTF2LkO3NFgh\|ryP	M4\CcHNCVkeHUh?=
RS4-11	M2rmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzlTWM2OD1zND63OFIh\|ryP	M1HWNnNCVkeHUh?=
MN-60	NWKxPI9PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3KwXGlEPTB;MUSuO\|g6PCEQvF2=	MXvTRW5ITVJ?
NCI-H1304	NWS0OFFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTF3LkC0NlUh\|ryP	NWHVdpNMW0GQR1XS
Ramos-2G6-4C10	NILt[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTF3LkC1PFEh\|ryP	MXPTRW5ITVJ?
NCI-H2342	Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPsUo1KSzVyPUG1MlIxPDRizszN	MVLTRW5ITVJ?
LAN-6	M4S0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrNV4VlUUN3ME2xOU41PDF2IN88US=>	M2KzPXNCVkeHUh?=
JVM-2	NF:yUIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTF3LkW3OFgh\|ryP	NX;TSnFKW0GQR1XS
P30-OHK	NVG2b5pOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnFT2NKSzVyPUG2MlA3OTRizszN	M2HpcHNCVkeHUh?=
C-33-A	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTF4Lk[yNVQh\|ryP	NVHibHQ3W0GQR1XS
RPMI-8866	NVzSTXlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnlbYtCUUN3ME2xOk45PDl4IN88US=>	MX7TRW5ITVJ?
NCI-H630	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTF4Lki1N\|ch\|ryP	MWnTRW5ITVJ?
KYSE-140	M4jvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;NTWM2OD1zNz6yNFI5KM7:TR?=	NVK5NmNlW0GQR1XS
T84	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrJfmJbUUN3ME2xPE45Pjl3IN88US=>	NFXOd3NUSU6JRWK=
KU-19-19	NIPoSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXwTnlKSzVyPUG4Mlk3ODhizszN	M37PS3NCVkeHUh?=
BALL-1	NYfwSWJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTF7LkOzPVkh\|ryP	MUDTRW5ITVJ?
Calu-6	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3EPYZKSzVyPUG5MlQ6OiEQvF2=	MnPLV2FPT0WU
EGI-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rKRmlEPTB;MUmuOVk5KM7:TR?=	MofYV2FPT0WU
MFH-ino	M1\u[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TQOWlEPTB;MUmuO\|Q2PCEQvF2=	NFf4TWtUSU6JRWK=
GB-1	M{XFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTJyLkO1N\|Uh\|ryP	MoLSV2FPT0WU
NCI-H1693	M{jYXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXG3d3pwUUN3ME2yNE43PTB3IN88US=>	NEHvVWlUSU6JRWK=
SW1116	NVzxW2ltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVT2bXRQUUN3ME2yNE46OzZ{IN88US=>	MXzTRW5ITVJ?
H-EMC-SS	NX\aV5FQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HzRmlEPTB;MkKuNFQ2KM7:TR?=	MV\TRW5ITVJ?
D-502MG	NVfwWWFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXUTWM2OD1{Mj64NlYyKM7:TR?=	MVLTRW5ITVJ?
IA-LM	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTJ\|LkK0PVMh\|ryP	NI\iZmJUSU6JRWK=
SW1463	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjabIZ1UUN3ME2yN{44QSEQvF2=	MUHTRW5ITVJ?
JAR	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH:zcohKSzVyPUK0MlMzQTNizszN	NIXp[HBUSU6JRWK=
HT	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTJ2LkS3OVMh\|ryP	MVzTRW5ITVJ?
LCLC-103H	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7YephKSzVyPUK0Mlg1PDlizszN	M{ntcnNCVkeHUh?=
SNU-449	NUfLTmNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTJ2Lki3OFEh\|ryP	M1XpPHNCVkeHUh?=
KE-37	NIrpb\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTJ3LkC5Nlgh\|ryP	MoLTV2FPT0WU
NCI-H1623	NXLCN4ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlz2TWM2OD1{Nz6xN\|A{KM7:TR?=	MWDTRW5ITVJ?
MOLT-13	NF\wcVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHPTWM2OD1{Nz6zOVE3KM7:TR?=	NIrVVZpUSU6JRWK=
COLO-741	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XXVGlEPTB;M{GuN\|M{OyEQvF2=	M1uzPHNCVkeHUh?=
NB6	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;DZ\|lKSzVyPUOyMlI5PzZizszN	NVXMUIVMW0GQR1XS
MOLT-16	M3\5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLW[4Y6UUN3ME2zN{4xODV3IN88US=>	MXfTRW5ITVJ?
IST-MES1	M2jFT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn21TWM2OD1\|ND6wOVQyKM7:TR?=	M2LUN3NCVkeHUh?=
A4-Fuk	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PEdWlEPTB;M{WuNFY3KM7:TR?=	MlGyV2FPT0WU
CAL-85-1	M3y0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XyN2lEPTB;M{WuNlgyPyEQvF2=	NGrIfJdUSU6JRWK=
CCRF-CEM	NF3HXm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTN5LkG1N\|Yh\|ryP	NYHUVXpbW0GQR1XS
HAL-01	NXzSXIZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTN6LkS4PFkh\|ryP	MnLrV2FPT0WU
HEL	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTR\|LkO0NFkh\|ryP	MXPTRW5ITVJ?
EW-1	M2[2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TJSWlEPTB;NEOuOFc3QCEQvF2=	MXnTRW5ITVJ?
MDA-MB-231	M1;6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mof4TWM2OD12NT6xNVk6KM7:TR?=	MVPTRW5ITVJ?
ABC-1	NGLHdGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHv3O4ZKSzVyPUS2Mlg2OzhizszN	NFrv[HhUSU6JRWK=
NCI-H446	NV35[oNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTR6LkWwOVgh\|ryP	NH\qU4ZUSU6JRWK=
MHH-PREB-1	Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTR7Lk[wNFch\|ryP	MVvTRW5ITVJ?
DOHH-2	NUDaR\|NmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDyTWM2OD12OT62OlU3KM7:TR?=	MoH6V2FPT0WU
GCT	NE\sRlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmqyTWM2OD12OT62PVc3KM7:TR?=	MVrTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	α-Synuclein / HSP90 / HSP70 / HSP32 / αB-Crystallin; PubMed: 20090920 PLoS One Immunoblot analysis of heat shock protein induction. Cells were treated with 17-AAG (1–200 nM, 24 h), or subjected to heat shock (HS: 44°C, 30 min, 24 h recovery) or to MG-132 (MG: 1 µM, 24 h). Cell lysates were prepared and immunoblot analysis was carried out with antibodies against the individual proteins as indicated on the right. Co, untreated control. EGFR / PDGFR / AKT / MAPK / c-RAS; PubMed: 18682579 Neuro Oncol 17-AAG promotes the degradation of HSP90 client proteins that are involved in the pathology of glioblastoma multiforme (GBM). Glioma cell lines were treated with increasing concentrations of 17-AAG for 48 h, and protein lysates were run on Western blots. HSP90 client proteins known to be involved in gliomagenesis showed degradation while nonclient proteins remained unaffected by 17-AAG treatment. pAKT / pMAPK / pRb; PubMed: 18682579 Neuro Oncol The phosphorylated states of signaling proteins involved in glioma growth are also affected by 17-AAG treatment. Cleaved PARP / Survivin; PubMed: 18827603 J Thorac Oncol Western analysis of expression levels of cleaved PARP and Survivin in MM cell lines. β-Actin served as loading control. LATS1 / p-LATS1 / YAP / CTGF; PubMed: 25712415 J Cell Mol Med Effects of 17-AAG on the expression of LATS1, p-LATS1, YAP and CTGF. The expression levels of YAP and CTGF proteins, indicated by Western blot assay, were down-regulated, while LATS1 was upregulated in a dose-dependent manner in 17-AAG treated groups compared to the untreated group.	20090920 18682579 18827603 25712415
Immunofluorescence	STAT3; PubMed: 27279418 Mol Med Rep Effects of 17-AAG on STAT3 expression of H446 cells. (A) Control group; (B) 3.125 mg/l; (C) 6.25 mg/l. 17-AAG, 17-allylamino-17-demethoxygel-danamycin; STAT3, signal transducer and activator of transcription 3; DAPI, 4′,6-diamidino-2-phenylindole. YAP / TAZ; PubMed: 25290150 PLoS One Reduction in cytoplasmic distribution accompanied by increased nuclear localization of YAP/TAZ was more apparent in cells treated with 45 nM 17-AAG (red channel for YAP/TAZ and blue channel for nucleus). Statistical comparisons were performed using one-way Kruskal-Wallis multiple comparison, ***p<0.001 compared with control (0 nM). β-catenin / E-cadherin; PubMed: 25290150 PLoS One Co-localization of β-catenin (Red) and E-cadherin (Green) was observed at the cell-cell junctions (white arrows) both in siCtrl and siCTGF cells after 17-AAG treatment. Scale bar is 20 µm.	27279418 25290150
Growth inhibition assay	Cell viability; PubMed: 18682579 Neuro Oncol 17-AAG inhibits the growth of human glioma cell lines. Human glioma cell lines and a nontumorigenic fibroblast cell line were treated with increasing concentrations of 17-AAG for 4 days, and the effect on cell growth was assessed by a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. The 50% inhibitory concentration (IC50) of all glioma cell lines ranged from 0.05 to 0.5 μM 17-AAG, as compared to 1.5 μM for the nontumorigenic cells.	18682579

In vivo

17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. ^[1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Hsp90 binding assays: Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl₂, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:^[1]	- Collapse Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 5 days Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A₄₉₀) of wells not containing cells is subtracted. Percentage of viable cells = (A₄₉₀ of 17-AAG treated sample/A₄₉₀ untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6 Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle Dosages: ~50 mg/kg Administration: Injection i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (170.73 mM)
	Ethanol	5 mg/mL (8.53 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+corn oil For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Tanespimycin (17-AAG) SDF

Molecular Weight	585.69
Formula	C₃₁H₄₃N₃O₈
CAS No.	75747-14-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	CP127374,NSC-330507, KOS 953
Smiles	COC1CC(C)CC2=C(NCC=C)C(=O)C=C(NC(=O)C(=C\C=C/C(OC)C(OC(N)=O)/C(=C/C(C)C1O)C)\C)C2=O

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00103272	Terminated	Drug: tanespimycin\|Drug: bortezomib	Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult T-cell Leukemia/Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Waldenström Macroglobulinemia	National Cancer Institute (NCI)	April 2005	Phase 1
NCT00098488	Terminated	Drug: tanespimycin\|Biological: rituximab	B-cell Chronic Lymphocytic Leukemia\|Prolymphocytic Leukemia\|Refractory Chronic Lymphocytic Leukemia	National Cancer Institute (NCI)	April 2005	Phase 1
NCT00118248	Completed	Drug: tanespimycin	Recurrent Thyroid Cancer\|Stage IV Follicular Thyroid Cancer\|Stage IV Papillary Thyroid Cancer\|Thyroid Gland Medullary Carcinoma	National Cancer Institute (NCI)	December 2004	Phase 2
NCT00098423	Completed	Drug: tanespimycin\|Drug: cytarabine	Accelerated Phase Chronic Myelogenous Leukemia\|Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Blastic Phase Chronic Myelogenous Leukemia\|Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndromes\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Refractory Anemia With Excess Blasts in Transformation\|Relapsing Chronic Myelogenous Leukemia\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndromes	National Cancer Institute (NCI)	November 2004	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?
Answer:
17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-DMAG (Alvespimycin) HCl : Phase II for Kidney Cancer.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (e.g. HSP90) Products

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Luminespib (NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)